Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $15.8 million.

  • China Pharma Holdings' Liabilities and Shareholders Equity rose 17.37% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.7 million, marking a year-over-year decrease of 2.83%. This contributed to the annual value of $14.9 million for FY2024, which is 9.60% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Liabilities and Shareholders Equity is $15.8 million, which was up 14.81% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Liabilities and Shareholders Equity registered a high of $22.6 million during Q4 2021, and its lowest value of $13.5 million during Q3 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $15.4 million (2023), whereas its average is $15.2 million.
  • Per our database at Business Quant, China Pharma Holdings' Liabilities and Shareholders Equity decreased by 21.48% in 2022 and then climbed by 17.37% in 2025.
  • China Pharma Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $22.6 million in 2021, then fell by 21.48% to $17.8 million in 2022, then fell by 7.39% to $16.5 million in 2023, then dropped by 9.60% to $14.9 million in 2024, then increased by 17.37% to $15.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $15.8 million for Q3 2025, versus $13.8 million for Q2 2025 and $14.2 million for Q1 2025.